India is aiming to raise its pharmaceutical exports to $50 billion by 2030, driven by expanding global demand for affordable medicines, growing manufacturing capabilities and continued government support for the sector. A senior government official said the target reflects India’s ambition to strengthen its position as a leading supplier of pharmaceutical products to markets across the world.
The country’s pharmaceutical exports have witnessed steady growth over the past decade, supported by a strong base of generic drug manufacturers, increasing investments in research and development, and expanding regulatory approvals in key markets. India currently exports medicines, vaccines, active pharmaceutical ingredients (APIs) and healthcare products to more than 200 countries and territories.
Government initiatives such as the Production Linked Incentive (PLI) scheme for pharmaceuticals and bulk drugs, along with efforts to enhance domestic API production, are expected to play a crucial role in achieving the export target. These measures aim to improve self-reliance, reduce dependence on imports and strengthen India’s competitiveness in global pharmaceutical supply chains.
Industry stakeholders believe rising healthcare spending, ageing populations and increasing demand for cost-effective medicines in both developed and emerging economies will create significant opportunities for Indian exporters. The sector is also expected to benefit from growing demand for biosimilars, specialty drugs and contract manufacturing services.
India has emerged as one of the world’s largest suppliers of generic medicines and vaccines, earning recognition as the “pharmacy of the world.” The country played a critical role in ensuring the supply of essential medicines and vaccines during the COVID-19 pandemic, further enhancing its reputation as a reliable pharmaceutical manufacturing hub.
To support future growth, the government and industry are focusing on improving quality standards, strengthening regulatory compliance and expanding market access through trade partnerships and international collaborations. Efforts are also underway to encourage innovation, boost research capabilities and develop advanced pharmaceutical manufacturing technologies.
With favourable global demand trends, a robust manufacturing ecosystem and policy support, India’s pharmaceutical industry is expected to remain a key contributor to the country’s export growth strategy. Achieving the $50 billion export milestone by 2030 would further cement India’s position as a major player in the global healthcare and pharmaceutical market.
